Royalty Pharma plc (RPRX)
Summary
RPRX Chart
Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating
Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive incremental royalty growth.
Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing
Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds like Promacta erosion and IRA-related pressure.
Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.
Royalty Pharma plc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 35,574 | $1.34M | $2.04M | $704,106.21 | 52.52% |
 Curtis Ellergodt Rothschild Investment LLC | 2,359 | $112,757.52 | $135,595.32 | $22,837.8 | 20.25% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 29,117 | $1.63M | $1.65M | $20,362.09 | 1.25% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 766,678 | $33.56M | $43.52M | $9.97M | 29.71% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 370 | $11,951.32 | $21,382.3 | $9,430.98 | 78.91% |
Royalty Pharma plc Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Chris Schott JP Morgan | 1,929.71 | $119,256.23 | $118,503.65 | -$752.58 | -0.63% |
| SS Steve Scala TD Cowen | 566.28 | $31,966.27 | $33,959.56 | $1,993.29 | 6.24% |
Royalty Pharma plc (RPRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Royalty Pharma plc ever had a stock split?
Royalty Pharma plc Profile
| Biotechnology Industry | Healthcare Sector | Pablo Legorreta CEO | NASDAQ (NGS) Exchange | G7709Q104 CUSIP |
| US Country | 100 Employees | 14 Aug 2026 Last Dividend | - Last Split | 25 Mar 1993 IPO Date |
Overview
Royalty Pharma plc operates as a vital facilitator in the biopharmaceutical industry, chiefly by participating as a purchaser of biopharmaceutical royalties and by funding innovations within the sector primarily in the United States. The company’s business activities extend to identifying, evaluating, and acquiring royalties on a wide array of biopharmaceutical therapies. Furthermore, Royalty Pharma engages in collaboration with various innovators, including academic institutions, research hospitals, not-for-profits, as well as small and mid-cap biotechnology firms, and large pharmaceutical companies, thereby positioning itself as an instrumental partner in the advancement of medical research and development. Founded in 1996 and headquartered in New York, New York, the firm leverages its expertise and financial resources to support the development and commercialization of innovative therapeutic solutions.
Products and Services
- Royalty Acquisition:
Royalty Pharma’s core business involves the acquisition of royalties on a diverse portfolio of biopharmaceutical therapies. By acquiring these royalties, the company invests in the future revenue of these therapies, providing upfront capital to innovators and organizations that can be used to fuel further research, development, and commercialization efforts. This model enables continuous support and funding across various stages of drug development and commercialization.
- Funding Innovations:
In addition to royalty acquisitions, Royalty Pharma is actively involved in funding innovations within the biopharmaceutical industry. The company provides financial resources for the development of new therapeutic solutions by entering into partnerships with innovators across the field. This includes working closely with academic institutions, research hospitals, not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical corporations. Through this service, Royalty Pharma plays a pivotal role in bridging the funding gap often encountered in the early stages of drug development and research.
- Portfolio of Royalties:
Royalty Pharma boasts a robust portfolio comprising royalties on approximately 35 commercial products and 14 development-stage product candidates. These products and candidates span a diverse range of therapeutic areas such as rare diseases, cancer, neuroscience, immunology, respiratory diseases, infectious diseases, hematology, and diabetes. By having stakes in various stages of product development and across multiple therapeutic areas, Royalty Pharma diversifies its investment and support, ultimately contributing to the development of innovative treatments and advancements in healthcare.
